Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: BEREN THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: BEREN THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BEREN THERAPEUTICS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · third_quarter · Q3
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEAM THERAPEUTICS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · third_quarter · Q3
Source: Senate LDA
Protect Patients from Costly Care Act
Client: AGIOS PHARMACEUTICALS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Protect Patients from Costly Care Act
Client: AGIOS PHARMACEUTICALS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
Client: AGIOS PHARMACEUTICALS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
Client: BEAM THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
Client: BEAM THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
Client: AGIOS PHARMACEUTICALS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Genomic Answers for Children’s Health Act of 2026
Client: BEREN THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Genomic Answers for Children’s Health Act of 2026
Client: BEREN THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Most Favored Patient Act of 2026
Client: BEAM THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Most Favored Patient Act of 2026
Client: BEAM THERAPEUTICS · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · third_quarter · Q3
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEREN THERAPEUTICS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · second_quarter · Q2
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEAM THERAPEUTICS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · second_quarter · Q2
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · second_quarter · Q2
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEREN THERAPEUTICS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · second_quarter · RR
Issues related to patient access to innovative therapies
BEAM THERAPEUTICS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · second_quarter · RR
Issues related to patient access to innovative therapies
AGIOS PHARMACEUTICALS via GRIDIRON PUBLIC AFFAIRS, LLC
2026 · second_quarter · RR
Issues related to patient access to innovative therapies